Meeting slides
Interactive presentation

An Introduction to NAFLD and NASH

Narrated by Stephen Harrison, MD
Suggested Readings

Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.

Armstrong MJ, et al. Lancet. 2016;387(10019):679-690.

Non-alcoholic fatty liver disease: an expanded review.

Benedict M, Zhang X. World J Hepatol. 2017;9(16):715-732.

Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action.

Bril F, Cusi K. Diabetes Care. 2017;40(3):419-430.

NAFLD: a multisystem disease.

Byrne CD, Targher G. J Hepatol. 2015;62(suppl 1):S47-S64.

Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial.

Cusi K, et al. Ann Intern Med. 2016;165(5):305-315.

Effect of canagliflozin treatment on intrahepatic triglycerides and insulin action in patients with type 2 diabetes (T2DM).

Cusi K, et al. Endocrine Society 2018. March 17-20, 2018; Chicago, IL. Abstract OR05-3.

Glucagon like peptide-1 receptor agonists for the management of obesity and non-alcoholic fatty liver disease: a novel therapeutic option.

Dhir G, Cusi K. J Investig Med. 2018;66(1):7-10.

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis.

Dulai PS, et al. Hepatology. 2017;65(5):1557-1565.

Algorithm to identify patients with an activity grade > 2 in type 2 diabetic patients with non-alcoholic fatty liver disease (NAFLD)—development in a large prospective multicenter UK study.

Eddowes P, et al. J Hepatol. 2018;68(suppl 1): S552

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis.

Friedman SL, et al. Hepatology. 2017;67(5):1754-1767.

Components of metabolic syndrome increase the risk of mortality in nonalcoholic fatty liver disease (NAFLD).

Golabi P, et al. Medicine (Baltimore). 2018;97(13):e0214.

Recent advances in nonalcholic fatty liver disease.

Greenfield V, et al. Curr Opin Gastroenterol. 2008;24(3):320-327.

Noninvasive imaging methods to determine severity of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Hannah WN Jr, Harrison SA. Hepatology. 2016;64(6):2234-2243.

Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: the Rotterdam study.

Koehler EM, et al. Hepatology. 2016;63(1):138-147.

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: a randomized, phase 2 trial.

Loomba R, et al. Hepatology. 2018;67(2):549-559.

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial.

Neuschwander-Tetri BA, et al. Lancet. 2015;385(9972):956-965.

Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and -δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening.

Ratziu V, et al. Gastroenterology. 2016;150(5):1147-1159.

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial.

Ratziu V, et a. Hepatology. 2010;51(2):445-453.

Management of NAFLD: a stage-based approach.

Rinella ME, Sanyal AJ. Nat Rev Gastroenterol Hepatol. 2016;13(4):196-205.

Treatment of NAFLD with diet, physical activity and exercise.

Romero-Gómez M, et al. J Hepatol. 2017;67(4):829-846.

The performance of vibration controlled transient elastography in a US cohort of patients with non-alcoholic fatty liver disease.

Tapper EB, et al. Am J Gastroenterol. 2016;111(5):677-684.

Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD.

Tapper EB, Loomba R. Nat Rev Gastroenterol Hepatol. 2018;15(5):274-282.

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.

Targher G, et al. Diabetes. 2005;54(12):3541-3546.

Extrahepatic manifestations of nonalcoholic fatty liver disease.

VanWagner LB, Rinella ME. Curr Hepatol Rep 2016;15(2):75- 85.

Linked Resources

Clinical Practice Guidelines

The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.

Chalasani N, et al. Hepatology. 2018;67(1):328-357.

EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease.

European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO). J Hepatol. 2016;64(6):1388-1402.

Clinical Resources

Histological Scoring System for Nonalcoholic Fatty Liver Disease.

Transplant Pathology Internet Services, 2009.

MELD Score (Model for End-Stage Liver Disease) (12 and older).

MD+CALC online calculator, 2016.

NAFLD (Non-Alcoholic Fatty Liver Disease) Fibrosis Score.

MD+CALC online calculator, 2016.

Patient Resources

American College of Gastroenterology (ACG) Patient Education and Resource Center.

The ACG website. provides a basic overview of NAFLD and includes patient-centered podcasts.

American Liver Foundation.

The American Liver Foundation website offers broad-based information and links to additional educational resources and support services for patients living with liver disease.

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Health Information Center.

The NIDDK website for NAFLD and NASH provides comprehensive patient-centered information and resources, including an overview of clinical-trial participation.

Related activities
1.25 CME/CE

The Nexus of NASH and T2DM

The Emerging Role of the Diabetologist

Faculty: Kenneth Cusi, MD, FACP, FACE (Chair); Stephen A. Harrison, MD (Virtual Professor); Arun J. Sanyal, MBBS, MD, FAASLD; Zobair M. Younossi, MD, MPH, FACP, FACG, AGAF, FAASLD
Release: 09/17/2018
Expiration: 09/16/2019